


# Capital Raise Presentation

**March 2025**



# Important Notice and Disclaimer

## Introduction

This investor presentation (**Presentation**) has been prepared by MedAdvisor Limited (ACN 145 327 617) (**MedAdvisor Solutions** or **Company**) and is dated 31 March 2025. This Presentation has been prepared in relation to a proposed capital raising comprising of a placement issuing fully paid ordinary shares in MedAdvisor (**New Shares**) (**Placement**) and a share purchase plan issuing New Shares to eligible shareholders (**SPP**). The following notice and disclaimer applies to this Presentation, and you are therefore advised to read it carefully before reading or making any other use of this Presentation or any information contained in this Presentation. Certain market and industry data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. None of the Company, its representatives or advisers have independently verified any such market or industry data provided by third parties or industry or general publications. By accepting this Presentation, you represent and warrant that you are entitled to receive this Presentation in accordance with the restrictions, and agree to be bound by the limitations, contained within it.

## Summary Information

The material in this presentation is general background information about MedAdvisor Solutions and its activities current as at the date of this Presentation. It is information given in summary form and does not purport to be complete, nor does it contain all the information which a prospective investor may require in evaluating a possible investment in MedAdvisor Solutions or that would be required in a prospectus, product disclosure statement or other disclosure document prepared in accordance with the requirements of the Corporations Act. The Presentation should be read in conjunction with the Company's other periodic and continuous disclosure announcements filed with the Australian Securities Exchange, which are available at [www.asx.com](http://www.asx.com). Information in this Presentation is not intended to be relied upon as advice to investors or potential investors and does not consider the investment objectives, financial situation or needs of any particular investor. Investors should consider these factors, and consult with their own legal, tax, business and/or financial advisor in connection with any investment decision.

## Not financial product advice

This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) nor any recommendation to acquire New Shares and does not and will not form any part of any contract for the acquisition of shares of MedAdvisor Solutions. Each recipient of the Presentation should make its own enquiries and investigations regarding all information in this Presentation including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of the Company and its subsidiaries (**MedAdvisor Group**) and the impact that different future outcomes might have on the Group.

Information in this Presentation is not intended to be relied upon as advice to investors or potential investors and has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and seek appropriate advice, including financial, legal, accounting and taxation advice appropriate to their jurisdiction. MedAdvisor Solutions is not licensed to provide financial product advice in respect of the New Shares. Cooling off rights do not apply to the acquisition of New Shares under the Placement.

## Not an offer

This Presentation is not and should not be considered an invitation or offer to acquire or sell Shares in MedAdvisor Solutions or any other financial products, or a solicitation to invest in or refrain from investing in, shares in MedAdvisor Solutions or any other financial products. This Presentation is for information purposes only and is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or any other law. It has not been, and is not required to be, lodged with the Australian Securities and Investment Commission (**ASIC**).

This Presentation does not constitute an offer to sell, or a solicitation of an offer to buy any securities in any jurisdiction. The distribution of this Presentation and the offer of securities is restricted in jurisdictions outside Australia. See the sub-section of this Presentation captioned "International Offering Jurisdictions" for more information. Any failure to comply with such restrictions could constitute a violation of applicable securities laws. In particular, this Presentation may not be released to US wire services or distributed in the United States. This Presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or any jurisdiction in which such an offer would be illegal. The New Shares have not been, and will not be, registered under the US Securities Act of 1933 or the securities laws of any state or other jurisdiction of the United States and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

The SPP will be made on the basis of the information to be contained in the SPP offer booklet to be prepared for eligible retail shareholders in Australia and New Zealand (**SPP Offer Booklet**) and made available following its lodgment with ASX. Any eligible shareholder in Australia and New Zealand who wishes to participate in the SPP should consider the SPP Offer Booklet before deciding whether to apply under the SPP. Anyone who wishes to apply for New Shares under the SPP will need to apply in accordance with the instructions contained in the SPP Offer Booklet and application form.

# Important Notice and Disclaimer Cont'd

## Financial Information

All information in this Presentation is in Australian dollars (\$) unless stated otherwise. A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding.

Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation and totals may vary slightly due to rounding. All references to financial years (FY) appearing in this Presentation are to the financial years ended on 30 June of the indicated year.

This Presentation has not been audited in accordance with the Australian Auditing Standards. Unaudited financial data contained within this presentation may be subject to change.

## Effect of rounding (if applicable)

Several figures, amounts, percentages, estimates and calculations of value in this Presentation are subject to the effect of rounding.

## Past performance

Information regarding past performance, including past share price information, given in this Presentation is given for illustrative purposes only and should not be relied upon (and is not) an indication of its future performance or condition. The historical financial information contained in this Presentation is, or is based on, information that has previously been released to the market.

## Disclaimer

Canaccord Genuity (Australia) Limited (ACN 075 071 466) and Peloton Capital Pty Ltd (ACN 149 540 018) (**Joint Lead Managers**) are the lead managers of the Placement and the SPP. To the maximum extent permitted by law, MedAdvisor Solutions, its related bodies corporate and their respective officers, directors, employees, advisers, partners, affiliates and agents (**MedAdvisor Parties**), and the Joint Lead Managers, their related bodies corporate and their respective officers, directors, employees, advisers, partners, affiliates and agents (**Joint Lead Manager Parties**), make no representation or warranty, express or implied, as to the accuracy, completeness, timeliness or reliability of the contents of this Presentation. To the maximum extent permitted by law, none of the MedAdvisor Parties nor the Joint Lead Manager Parties accept any liability (without limitation, any liability arising from fault or negligence) for any loss whatsoever arising from the use of or reliance on this Presentation or its contents or otherwise arising in connection with it. None of the Joint Lead Manager Parties, have authorised, permitted or caused the issue, submission, dispatch or provision of this Presentation and, except to the extent referred to in this Presentation, none of them makes or purports to make any statement in this Presentation and there is no statement in this Presentation which is based on any statement by any of them. None of the MedAdvisor Parties nor the Joint Lead Manager Parties make any recommendation as to whether you or your related parties should participate in the Placement or SPP nor do they make any representations or warranties to you concerning the Offer.

By accepting this Presentation, you expressly disclaim that you are in a fiduciary relationship with any of the Joint Lead Manager Parties.

The Joint Lead Managers may have interests in the securities of MedAdvisor Solutions, including by providing investment banking services to MedAdvisor Solutions. Further, the Joint Lead Managers may act as market maker or buy or sell those securities or associated derivatives as principal or agent. The Joint Lead Managers may receive fees for acting as joint lead managers to the Placement and the SPP.

## Forward-looking statements and forecasts

This Presentation may contain “forward-looking” statements including statements, guidance, forecasts, estimates, prospects, projections or statements in relation to future matters, including statements regarding MedAdvisor Solutions’ intent, belief or current expectations with respect to its business operations, market conditions, results of operations, financial conditions, and risk management practices. Forward-looking statements can generally be identified by the use of forward-looking words such as “anticipated”, “expected”, “aim”, “predict”, “projections”, “should”, “plans”, “guidance”, “forecast”, “estimates”, “could”, “may”, “target”, “consider”, “will” and other similar expressions. Indications of, and guidance on, future earnings, financial performance, and financial position are also forward-looking statements. Forward-looking statements including projections, indications or guidance on future earnings or financial position and estimates are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. The forward-looking statements contained in this Presentation involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of the Company and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Forward-looking statements may also assume the success of the Company’s business strategies and no assurance can be given that any of the strategies will be effective or that the anticipated benefits from the strategies will be realised in the period for which the forward-looking statements may have been prepared or otherwise.

Forward-looking statements, opinions and estimates are based on assumptions and contingencies which are subject to certain risks, uncertainties and change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Many of these risks are not in the control of MedAdvisor. Should one or more of the risks or uncertainties materialise, or should underlying assumptions prove incorrect, there can be no assurance that actual outcomes will not differ materially from these statements. No independent third party has reviewed the reasonableness of these forward-looking statements. You should not place undue reliance on forward-looking statements and neither MedAdvisor Solutions nor any of its directors, employees, advisers or agents assume any obligation to update such information.

# Important Notice and Disclaimer Cont'd

## **Forward-looking statements and forecasts (cont.)**

No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including the Company or any of its advisers). In particular, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statements in this Presentation will actually occur. Actual operations, results, performance, production targets or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based.

To the fullest extent permitted by law (including the ASX Listing Rules), the MedAdvisor Parties disclaim any obligation or undertaking to release any updates or revisions to the information to reflect any change in expectations or assumptions. Except as required by law, none of the MedAdvisor Parties assume any obligation to release any updates or revisions to forward-looking statements to reflect any changes.

## **Investment risk**

An investment in securities in MedAdvisor Solutions is subject to known and unknown risks, some of which are beyond the control of the MedAdvisor Group. MedAdvisor Solutions does not guarantee any particular rate of return or the performance of the MedAdvisor Group, nor does it guarantee any particular tax treatment. Investors should have regard to the risk factors outlined in this Presentation when making their investment decision and should make their own enquiries and investigations regarding all information in this Presentation, including the assumptions, uncertainties and contingencies which may affect future operations of the MedAdvisor Group and the impact that different future outcomes may have on the MedAdvisor Group.

## **General**

The distribution of this Presentation to persons or in jurisdictions outside Australia may be restricted by law and any person into whose possession this Presentation comes should seek advice on and observe those restrictions.

Any failure to comply with such restrictions may violate applicable securities law. No party other than MedAdvisor Solutions has authorised, permitted, caused the issue, submission, dispatch or provision of this Presentation, or takes any responsibility for, or makes or purports to make any statements, representations or undertakings in this Presentation. None of the MedAdvisor Parties take any responsibility for the information in this Presentation or any action taken by the recipient on the basis of such information.

To the maximum extent permitted by law, the MedAdvisor Parties:

- exclude and disclaim all liability, including for negligence, or for any expenses, losses, damages or costs incurred by you as a result of your participation in the Offer and the information in this Presentation being inaccurate or incomplete in any way for any reason, whether by negligence or otherwise; and
- make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this Presentation.

Determination of eligibility of investors for the purpose of the Offer is determined by reference to a number of matters, including legal requirements and the discretion of MedAdvisor Solutions and the Joint Lead Managers. The MedAdvisor Parties and Joint Lead Manager Parties disclaim any liability in respect of the exercise or otherwise of that discretion, to the maximum extent permitted by law.

## **International Offer Restrictions**

This Presentation does not constitute an offer of New Shares in the Company in any jurisdiction in which it would be unlawful. In particular, this Presentation may not be distributed to any person, and the New Shares may not be offered or sold, in any country outside Australia except to the extent permitted below.

## **New Zealand**

This Presentation has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013 (**FMC Act**).

The New Shares may only be offered or sold in New Zealand (or allotted with a view to being offered for sale in New Zealand) to a person who:

- is an investment business within the meaning of clause 37 of Schedule 1 of the FMC Act;
- meets the investment activity criteria specified in clause 38 of Schedule 1 of the FMC Act;
- is large within the meaning of clause 39 of Schedule 1 of the FMC Act;
- is a government agency within the meaning of clause 40 of Schedule 1 of the FMC Act; or
- is an eligible investor within the meaning of clause 41 of Schedule 1 of the FMC Act.

# Important Notice and Disclaimer Cont'd

## Hong Kong

WARNING: This Presentation has not been, and will not be, registered as a prospectus under the *Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32)* of Hong Kong, nor has it been authorised by the Securities and Futures Commission in Hong Kong pursuant to the *Securities and Futures Ordinance (Cap. 571)* of the Laws of Hong Kong (SFO). Accordingly, this Presentation may not be distributed, and the New Shares may not be offered or sold, in Hong Kong other than to "professional investors" (as defined in the SFO and any rules made under that ordinance).

No advertisement, invitation or document relating to the New Shares has been or will be issued, or has been or will be in the possession of any person for the purpose of issue, in Hong Kong or elsewhere that is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to New Shares that are or are intended to be disposed of only to persons outside Hong Kong or only to professional investors. No person allotted New Shares may sell, or offer to sell, such securities in circumstances that amount to an offer to the public in Hong Kong within six months following the date of issue of such securities.

The contents of this Presentation have not been reviewed by any Hong Kong regulatory authority. You are advised to exercise caution in relation to the offer. If you are in doubt about any contents of this Presentation, you should obtain independent professional advice.

## Singapore

This Presentation and any other materials relating to the New Shares have not been, and will not be, lodged or registered as a prospectus in Singapore with the Monetary Authority of Singapore. Accordingly, this Presentation and any other document or materials in connection with the offer or sale, or invitation for subscription or purchase, of New Shares, may not be issued, circulated or distributed, nor may the New Shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore except pursuant to and in accordance with exemptions in Subdivision (4) Division 1, Part 13 of the *Securities and Futures Act 2001* of Singapore (SFA) or another exemption under the SFA.

This Presentation has been given to you on the basis that you are an "institutional investor" or an "accredited investor" (as such terms are defined in the SFA). If you are not such an investor, please return this Presentation immediately. You may not forward or circulate this Presentation to any other person in Singapore.

Any offer is not made to you with a view to the New Shares being subsequently offered for sale to any other party in Singapore. On-sale restrictions in Singapore may be applicable to investors who acquire New Shares. As such, investors are advised to acquaint themselves with the SFA provisions relating to resale restrictions in Singapore and comply accordingly.

## United Kingdom

Neither this Presentation nor any other document relating to the offer has been delivered for approval to the Financial Conduct Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the *Financial Services and Markets Act 2000*, as amended (FSMA)) has been published or is intended to be published in respect of the New Shares.

The New Shares may not be offered or sold in the United Kingdom by means of this Presentation or any other document, except in circumstances that do not require the publication of a prospectus under section 86(1) of the FSMA. This Presentation is issued on a confidential basis in the United Kingdom to "qualified investors" within the meaning of Article 2(e) of the UK Prospectus Regulation. This Presentation may not be distributed or reproduced, in whole or in part, nor may its contents be disclosed by recipients, to any other person in the United Kingdom.

Any invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) received in connection with the issue or sale of the New Shares has only been communicated or caused to be communicated and will only be communicated or caused to be communicated in the United Kingdom in circumstances in which section 21(1) of the FSMA does not apply to the Company.

In the United Kingdom, this Presentation is being distributed only to, and is directed at, persons (i) who have professional experience in matters relating to investments falling within Article 19(5) (investment professionals) of the *Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (FPO)*, (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated (together "relevant persons"). The investment to which this Presentation relates is available only to relevant persons. Any person who is not a relevant person should not act or rely on this Presentation.



Executive  
Summary





# Executive Summary

<b>MedAdvisor Overview</b>	<ul style="list-style-type: none"><li>• MedAdvisor Limited (<b>MedAdvisor Solutions</b> or <b>Company</b>) provides medication management solutions in Australia, New Zealand and the United States.</li><li>• MedAdvisor Solutions is a global leader of innovative, pharmacy-driven patient engagement solutions that provide individualised patient experiences to help remove barriers to care.</li><li>• The group delivered 1H FY25 group revenue of \$57.1M and positive EBITDA of \$4.8m.</li></ul>
<b>Revenue Acceleration and Cost Optimisation</b>	<ul style="list-style-type: none"><li>• Significant revenue pipeline growth and diversification driven by the restructure of the sales team, customer success function and pharmacy network teams in the US.</li><li>• Transformation 360<sup>o</sup> on time and on budget to deliver A\$5.0m in cost savings in FY26.</li><li>• Additional cost outs identified and being implemented to deliver a further reduction to OPEX of A\$3.4m in FY26.</li></ul>
<b>Strategic Review</b>	<ul style="list-style-type: none"><li>• Strategic review commenced in November 2024 to address valuation disconnect. The review considers a range of corporate actions including change of control transactions (i.e. divestment or acquisition), cost optimisation programs and organic growth initiatives.</li><li>• Received strong interest in the Australian business with several conditional, non-binding proposals received from third parties.</li><li>• Completion of review, with announcement of outcome(s), on or before 30 June 2025.</li><li>• Linda Jenkinson steps down as Chair and from the Board to focus on other priorities. Kate Hill appointed as Interim Chair.</li></ul>
<b>Outlook</b>	<ul style="list-style-type: none"><li>• Business transformation and cost out initiatives reset the business for revenue and earnings growth.</li><li>• Anticipated revenue for FY25 of A\$93M – A\$99m.</li><li>• Forecast Group-level revenue growth of circa 15% and margin expansion in FY26.</li></ul>
<b>Equity Raise</b>	<ul style="list-style-type: none"><li>• MedAdvisor Solutions is seeking to raise A\$5.0 million by way of an institutional placement (<b>Placement</b>) and a share purchase plan (<b>SPP</b>) to eligible shareholders to raise up to A\$2.0 million (Placement and SPP collectively referred to as the <b>Offer</b>). Neither the Placement nor the SPP will be underwritten. The Company may accept oversubscriptions in the Placement at its absolute discretion.</li><li>• Offer Price of A\$0.10 per share representing an 9.1% discount to last close and 1.2% discount to 5-Day VWAP (as at 28 March 2025).</li><li>• Proceeds from the Offer will be used for working capital to continue executing on strategic and cost out initiatives.</li></ul>



# Company Update

**MedAdvisor Solutions** is a global leader of innovative, pharmacy-driven patient engagement solutions that provide individualised patient experiences to help remove barriers to care.

## Profit

Delivered 1H FY25 group revenue of \$57.1M and **positive EBITDA** of \$4.8m.

Optimised cost base to significantly reduce fixed costs going forward.

## US

US saw growth in higher margin THRiV powered patient engagement programs which now **represents nearly 35% of 2Q FY25 revenue.**

Robust and diversified pipeline for the US business.

## ANZ

ANZ business **continues to grow** with the launch of new services and revenue streams, including telehealth and e-commerce.

**Transitioned 90% of Australian pharmacies** to cloud-based, MedAdvisor for Pharmacy platform.

## Value

Initiated review of **strategic options** to consider a range of corporate actions including change of control transactions (i.e. divestment or acquisition), cost optimisation programs and organic growth initiatives.


Group level business redesign initiative, Transformation 360<sup>0</sup> is **on time and on budget.**



Company  
Overview



# Company Overview



## Our Focus

**US:** Primary focus is targeted patient engagement programs for pharma, delivered through the patient's pharmacy.

- Each delivered communication generates a transaction fee.
- As US programs transition to an **omnichannel** approach, powered by our AI enabled platform, **THRiV**, the transaction fee shifts to a per-patient model.

**ANZ:** SaaS platform supports the pharmacist's workflow and generates subscription and transaction fees.

- Pharmacy pays a subscription fee for **MedAdvisor for Pharmacy** and ability to distribute at no cost the **MedAdvisor consumer app**.
- SMS/Text, flu/vaccine scheduling, monitoring and commerce services generate transaction fees.
- Pharma-sponsored programs generate transaction fees.

## Our impact



**The Patient**  
Simplifying the patient journey

>200M patients



**The Pharmacy**  
Empowering the pharmacy of the future

>37,000 pharmacy locations



**Pharma**  
Improving access to medications

16 of top 20 pharma manufacturers



# 1H FY25 Results & Initiatives

## Results

- EBITDA: Remained positive despite a challenging trading environment in the US.
- Gross margin: Increase driven by a higher mix of digital engagement and THRiV-powered programs in the US.
- Revenue: Declined year-over-year due to the accelerated realisation of anticipated revenue concentration risks.

## Initiatives

- Macro headwinds in the US contributed to the acceleration of planned sales restructuring and cost optimisation programs.
- Sales restructuring in early FY25 lacked time to mitigate revenue concentration risks, highlighting the need for faster action.
- Completion of cost out process identified by management along with other initiatives outlined will see a significant reduction in OPEX for the full year FY25 of ~A\$4.5m pcp.

## 1H FY25 revenue of

\$57.1M down 24.4% YOY



## 1H FY25 gross profit of

\$35.0M down 19.4% YOY



## 1H FY25 EBITDA of

\$4.8M vs \$10.4m in PCP





Revenue  
Acceleration  
and Cost  
Optimisation





# US Business – Positioned for Growth

## Addressing FY25 Challenges, Capturing Market Opportunities

### Sales Execution

Underperforming US commercial organisation impacting growth

- Low-level sales engagement & limited customer diversification
- Small, inexperienced sales team lacking automation & discipline
- Operationally-focused account management
- Slow pharmacy network innovation



Actions taken and underway:

- Restructured sales team with appointment of experienced leadership (early FY25) and cut underperformers
- Revamping customer success function by optimising headcount and team structure for greater efficiency and effectiveness
- Reorganised pharmacy network team to improve strategic focus

### Market Trends – Challenges and Growth Opportunities

Dynamics in pharma creating challenges & opportunities

- Period of reduced vaccination rates resulting in sudden & significant budget cuts
- Buyer shift towards DTC: extending sales cycles & affecting contract values
- Rising direct & indirect digital / omnichannel competition
- Customer R&D & marketing budgets reallocated to specialty medications

Tailwinds MDR is positioned to capitalise on:

- Transformation 360<sup>0</sup> on-track with new platform to launch in Q2 FY26 to significantly reduce fixed costs
- Strong indications of a rebound in vaccination programs in Aug / Sept FY26
- Momentum building within the specialty medication segment – with >60% of US spending on this category and a good fit for MDR's channels
- Pharma shifting spend toward targeted digital engagement solutions



# US Business – Revenue and Pipeline

## Primed for Accelerated Growth and Margin Expansion in FY26


### Outlook

- While trading conditions remained challenging through Q3 as the business transitions, there is an expectation of a stronger Q4 with **anticipated revenue of US\$14-18m in 2H FY25** with 70-90% currently contracted.
- Expectation that a further 15% will be contracted in the coming weeks for a total of 80-100% of projected revenue under contract.
- Current diversification strategy delivering a **significantly larger and more diversified pipeline**.
- Forecasting circa 15% CAGR revenue growth organically in FY26.


### Strategic Initiatives

- Optimise sales cycle to **drive pipeline conversion**.
- Drive growth through **reshaping of business processes and go-to-market (GTM) strategy**.
- **Triple-layered pipeline diversification**: by brand/manufacturer, across categories, and within categories
- Launch THRiV next-gen patient engagement platform in the US to **increase gross margins**.

### Pipeline by Category



### US Pipeline Diversification



\*the Company's pipeline is forward-looking and subject to risks and uncertainties. There is no guarantee that these contracts will be finalised, that the projected values will be realised or any certainty around the timing of such contract wins. The Company does not have a sufficient reliable sample of historical rates of conversion of its sales pipeline.



# ANZ Business


## Market Leader with Strong Track Record and Forecasted Growth

### Focused Strategic Initiatives

- Continue price restructuring by standardising SaaS fees.
- Leverage recently announced Women’s Health initiative to accelerate ROI from scope of practice investment.
- Complete MedAdvisor for Pharmacy platform migration in ANZ.

### Clear Pathways for Additional Growth

- Increased transaction fees aligned with value to customers
- Expanded pharmacy solutions such as telehealth and ecommerce
- Monetise Expanded Scope of Practice (ESoP) programs
- Enhanced AI workflow solutions



**98%**

Access to 98% of patients accessing prescriptions.

**95%**

Pharmacies using MedAdvisor for Pharmacy.

**72%**

Recurring revenues from SaaS and transaction fees.

Trusted by the leading pharmacy groups including:






# Accelerated Cost-Out Program

**Delivering ~A\$12.8m<sup>1</sup> Savings between FY24 to FY26 through New Targeted Cost-Out Initiatives and Transformation 360<sup>0</sup>**

- Total expected savings in FY25 and FY26 is A\$4.5m and A\$8.4m, respectively.
- Expected OPEX savings resulting from the implementation of Transformation 360<sup>0</sup> is A\$1.4m in FY25 and A\$5.0m in FY26.
- Expected savings because of the new cost-out initiatives is A\$3.1m of FY25 and A\$3.4m in FY26.
- Headcount reduction in FY25 of ~44% in the US and ~15% in ANZ.
- Management forecasts a steady reduction in operating expenses, with OPEX projected to decrease from A\$67.4m in FY24 to A\$62.9m in FY25 and A\$54.5m in FY26.

## Projected OPEX



**Management and the Board are laser-focused on market conditions and sales performance, remaining agile and ready to make further changes as needed**

<sup>1</sup> the discrepancy between A\$12.8m and the sum of A\$4.5m and A\$8.4m is due to rounding.



# Strategic Review

## Addressing the Valuation Disconnect

### Strategic Review Update

- As announced to the market on 14 November 2024, the Company is currently undertaking a formal strategic review process to evaluate strategic options to maximise shareholder value. It is of the belief of the Board that MedAdvisor Solutions' current market valuation does not reflect the combined value of its Australian and US business units.
- The process is considering a range of corporate actions include change of control transactions (i.e. strategic acquisitions and divestments), targeted cost reductions, revised organic growth initiatives and actions to support capital management.
- While no specific decisions have been made at this stage, findings of the review continue to be refined in alignment with the Company's stated objective of maximising shareholder value and maintaining the Company's position as a leader in pharmacy-driven patient engagement.
- The Company confirms it has received strong interest in its Australian business as part of the process to date, and has received several conditional, non-binding proposals from third parties. The Company is currently assessing these proposals and will keep the market fully informed if any proposals develop into a formal transaction.
- The Company expects the review process to be completed by 30 June 2025.

### Board Changes

- Linda Jenkinson has announced her decision to step down as Chair and from the board to focus on other priorities in the US. Current non-executive director, Kate Hill has been appointed interim chair. The Board changes take effect 1 April 2025. To ensure a smooth transition, Linda will continue to provide support as the Company appoints a permanent chair.



# Outlook

## Positioned for strong growth and higher margins

### Key Investment Highlights


- Strengthened US sales structure to de-risk and accelerate revenue growth
- Margin expansion via Launch of THRiV next-gen patient engagement platform in the US
- Enhanced fee models and new service offerings driving growth in ANZ.
- Ongoing business optimisation and targeted cost reductions to drive profitability.

### Targeted Growth

- Forecast Group-level revenue growth of circa 15% and margin expansion in FY26.


### Revenue and EBITDA Guidance FY25

	FY 23a	FY 24a	FY 25e
<b>Revenue</b>	A\$98.0m	A\$122.1m	A\$93m – A\$99m
<b>Gross Profit</b>	A\$59.4m	A\$74.2m	A\$57m - A\$60m
<b>Gross Margin</b>	60.6%	60.8%	60.8% - 61.6%
<b>EBITDA</b>	(A\$3.0m)	A\$7.0m	(A\$2.6m) – (A\$5.5m)



# Equity Raise





# Transaction overview

Offer Structure & Pricing	<ul style="list-style-type: none"><li>• MedAdvisor Solutions is seeking to raising A\$5.0 million by way of Placement and up to A\$2.0 million via SPP (<b>Offer</b>).</li><li>• Offer Price of A\$0.10 per security represents a:<ul style="list-style-type: none"><li>• 9.1% discount to the last traded price on 28 March 2025 (A\$0.11)</li><li>• 1.2% discount to the 5-day VWAP price (A\$0.101)</li></ul></li><li>• MedAdvisor Solutions will issue approximately:<ul style="list-style-type: none"><li>• 50.0 million New Shares under the Placement representing approximately 9.1% of existing shares on issue; and</li><li>• up to 20.0 million New Shares under the SPP representing approximately 3.6% of existing shares on issue.</li></ul></li><li>• Neither the Placement nor the SPP will be underwritten.</li></ul>
Use of Proceeds	<ul style="list-style-type: none"><li>• Proceeds from the Offer will be used to continue executing on strategic and cost optimisation initiatives and working capital.</li></ul>
Ranking	<ul style="list-style-type: none"><li>• New Shares issued will rank equally with existing ordinary shares from allotment.</li></ul>
Director Participation	<ul style="list-style-type: none"><li>• The MedAdvisor Board intends to participate up to the total value of \$375,000 in the Placement. This will be subject to shareholder approval at an Extraordinary General Meeting to be expected to be held in late May 2025.</li></ul>
Joint Lead Managers	<ul style="list-style-type: none"><li>• Canaccord Genuity and Peloton Capital are acting as Joint Lead Managers to the Offer.</li></ul>



# Transaction overview (cont.)

## Transaction overview and post raise structure

MDR Pre Structure	
Shares Outstanding (m)	552.0
Share Price (A\$)	0.11
Market Capitalisation (A\$m)	60.7
MDR Post Structure	
Shares Outstanding (m)	622.0
Market Capitalisation (A\$m)	67.7
TERP (A\$)	0.109

Placement	
Placement Shares Issued (m)	50.0
Issue Price (A\$)	0.10
Placement Capital Raised (A\$m)	5.0
SPP	
SPP Shares Issued (m)	20.0
Issue Price (A\$)	0.10
SPP Capital Raised (A\$m)	2.0
TOTAL	
Total New Shares Issued (m)	70.0
Total Capital Raised (A\$m)	7.0



# Indicative Transaction Timetable

Key events	Indicative Dates*
Record Date for SPP	7.00pm (AEST) Monday, 31 March 2025
Trading Halt, Placement and SPP announced, Placement bookbuild conducted	Monday, 31 March 2025
Trading halt lifted and trading resumes	Tuesday, 1 April 2025
Settlement of Placement and SPP Offer opens / booklet made available	Monday, 7 April 2025
Allotment and normal trading of New Shares under Placement	Tuesday, 8 April 2025
SPP Offer closes	5.00pm (AEST) Thursday, 17 April 2025
SPP results announced and Settlement of funds for SPP	Wednesday, 23 April 2025
Allotment of New Shares under SPP, dispatch of holding statements and announcement of Extraordinary General Meeting	Thursday, 24 April 2025
Extraordinary General Meeting to approve Director participation	Monday, 26 May 2025
Expected Settlement of the New Shares under Tranche Two	Thursday, 29 May 2025
Expected date of ASX quotation of the New Shares under Tranche Two	Friday, 30 May 2025

Note: The above timetable is indicative only and subject to change. The commencement of trading and quotation of New Shares issued under the Placement and SPP is subject to confirmation from ASX. Subject to the requirements of the Corporations Act, the ASX Listing Rules and other applicable rules, MDR reserves the right to amend this timetable at any time, including extending the period for the SPP or accepting late applications, either generally or in particular cases, without notice. All times above are to Melbourne, Australia time.



# Key Risks





# Key Risks

Risk	Description	Risk	Description
<b>Capital management</b>	The objective of MedAdvisor’s capital management strategy is to maintain a strong financial position to support our current operations, prepare for future plans and to maximise shareholder value. MedAdvisor’s current focus is on monitoring our capital and liquidity position and ensuring our performance indicators are aligned with key financial metrics. If further debt or equity financing is required, it will be assessed against the potential impact on current share holdings and the current share price.	<b>Rising instability of revenue due to digital transformation and emerging competitors</b>	Increased competition through local or global competitors could result in price reductions, under-utilisation of personnel, assets or infrastructure, reduced operating margins or loss of market share, any of which could have an adverse impact on MedAdvisor’s financial performance. Further, if a potential for unstable revenue streams is realised, coupled with a need to increase investment to accelerate our roadmap delivery, then this could also adversely impact MedAdvisor’s profitability. A key focus will be on seeking new leads for new work by fostering relationships with new and existing customers and protecting or increasing barriers to entry for competitors where possible.
<b>Loss or theft of data and failure of data security systems and unauthorised use of personal information</b>	MedAdvisor’s products involve the storage of customers’ and patients’ confidential and proprietary information including health information. MedAdvisor Solution’s business could be materially impacted by security breaches as a result of unauthorised access, theft or misappropriation resulting in data being stolen. There is a risk that any measures taken may not be sufficient to prevent or detect unauthorised access to such information. We will continue to manage this risk with technology solutions and ongoing threat monitoring. Migrating key infrastructure to a cloud-based environment and regular information security auditing and privacy assessments will further reduce vulnerabilities and their potential impact.	<b>Disruption or failure of technology and software systems</b>	MedAdvisor and its customers are dependent on the performance, reliability and availability of its platforms, data centres and communications systems. There is a risk that these systems may be adversely affected by disruption, failure or outage. MedAdvisor will continue to conduct disaster recovery testing and business continuity planning periodically. Undertaking additional testing prior to releasing software and ensuring third party service levels are upheld will further reduce the likelihood of this risk.
<b>Access to patient prescription data</b>	The successful continuation of MedAdvisor’s health messaging platforms will depend on continued access to patient prescription data, which is dependent on permissions given by the pharmacy, retailer or patient as appropriate. If a significant number of customers or patients were to withdraw their consent for MedAdvisor to use prescription data, then that may have a material impact on our business. There is also a risk that Governments may legislate to limit or prohibit the access of prescription data by commercial organisations. MedAdvisor will continue to focus on building strong relationships with key stakeholders to maintain trust	<b>Loss of key personnel or skilled workers</b>	MedAdvisor’s ability to be productive, profitable and competitive and to implement our planned roadmap of initiatives depends on the continued employment and performance of senior management. MedAdvisor’s performance also depends on its ability to attract and retain skilled talent with relevant industry and technical experience. The interim focus will be to build on staff engagement feedback and continue to foster a corporate culture based on our mission and values.
<b>Concentration of customers and poor rebranding</b>	The revenue of MedAdvisor’s US business is highly concentrated with a small number of pharmaceutical manufacturers. If any one of these key customers ceased or significantly reduced its business with MedAdvisor, then this may have a material adverse impact on financial and operating performance. Further, our recent rebranding to MedAdvisor Solutions could lead to a loss of goodwill and reduce our brand awareness if not completed well. The next focus will be on diversifying the US portfolio of products and customers and consolidating the global transition to the MedAdvisor Solutions brand.	<b>Regulatory risk</b>	MedAdvisor operates in a complex and changing regulatory environment across multiple jurisdictions. Risks associated with compliance and changes to the regulatory environment may result in higher compliance costs or make certain products less profitable. Any breach of security could result in significant financial penalties and breach of contract. Further, the impact of a data breach would likely result in the loss of contracts and reputational damage to MedAdvisor. A key focus will be monitoring for emerging changes in the regulatory environment, assessment of new products and services and continuing assessment of potential legal risks.



# Key Risks (cont.)

Risk	Description	Risk	Description
<b>Insurance risk</b>	MedAdvisor may be adversely impacted if we are unable to obtain adequate insurance coverage for business risks. MedAdvisor maintains insurance coverage that is consistent with industry practice, however the level of coverage, premiums payable and potential deductibles in the event of a claim, may be impacted by various factors including lack of competing insurers, inherent limitations of insurance policies available in the market, exclusions, or the ability to obtain insurance beyond certain limits. Ongoing focus for MedAdvisor will be reviewing and rejecting products and services that result in unreasonable risk and working with insurers and brokers to ensure we obtain good value and coverage for the risks that are insured.	<b>Economic risk</b>	Changes in Australian, US and world economic conditions may adversely affect the financial performance of MedAdvisor. Factors such as inflation, currency fluctuations, interest rates, industrial disputes and economic growth may impact on future operations and earnings.
<b>Litigation risk</b>	MedAdvisor may be subject to litigation and other disputes and claims in the ordinary course of business. Pharmaceutical manufacturers, pharmacy groups and retailers are frequently the subject of class actions and other litigation. MedAdvisor could become a party to such litigation. Any litigation, dispute or claim could have a detrimental impact on MedAdvisor's current performance and reputation. MedAdvisor's ongoing focus will be to assess products with high-risk profiles and ensure approved delegations of authority are strictly followed.	<b>Force majeure</b>	MedAdvisor's projects now or in the future may be adversely affected by risks outside the control of MedAdvisor, including labour unrest, civil disorder, war, subversive activities or sabotage, fires, floods, pandemics, explosions or other catastrophes, epidemics or quarantine restrictions.
<b>Intellectual property</b>	There can be no assurances that the validity, ownership or authorised use of intellectual property (including technology, know-how, trademarks, designs and patents (both owned and licensed) relevant to the Group's business will not be challenged which could adversely affect the Group's financial and operating performance.	<b>Other risks</b>	The above risks should not be taken as a complete list of the risks associated with an investment in New Shares. The risks outline above and other risks specifically referred to may in the future materially adversely affect the value of MedAdvisor shares and the financial performance of the Company. No assurance or guarantee of future performance or profitability of MedAdvisor or the value of MedAdvisor shares is given.
<b>General market and share price risks</b>	General economic factors such as interest rates, exchange rates, inflation, business and consumer confidence and general market factors may have an adverse impact on MedAdvisor's performance, prospects or the value of its assets. The market price of MedAdvisor shares will fluctuate due to various factors, many of which are non-specific to MedAdvisor, including recommendations by brokers and analysts, Australian, US and international general economic conditions, inflation rates, interest rates, exchange rates, changes in government, fiscal and monetary and regulatory policies, changes to laws, global investment markets, global geo-political events and hostilities, investor perceptions and other factors that may affect MedAdvisor's financial performance and position. In the future, these factors may cause MedAdvisor shares to trade at or below their current price.		

Thank you!



# Appendix



# Covenants & Balance Sheet

## 1. Minimum Revenue Covenant

At the end of each month listed in the first column of the table below and in respect of the previous six-month period ending on the last day of that month set out in the second column of the table below beside each such month, the average Monthly Revenue of MedAdvisor over such six-month period must be equal to or exceed the amount set out in the corresponding third column of the table as follows:

Month	Relevant 6-month trailing period	Minimum trailing 6-month average revenue (in A\$)
Sep 24	1 Apr 24 – 30 Sep 24	A\$4,500,000
Oct 24	1 May 24 – 31 Oct 24	A\$4,500,000
Nov 24	1 Jun 24 – 30 Nov 24	A\$5,500,000
Dec 24	1 Jul 24 – 31 Dec 24	A\$5,500,000
Jan 25	1 Aug 24 – 31 Jan 25	A\$5,500,000
Feb 25	1 Sep 24 – 28 Feb 25	A\$5,500,000
Mar 25	1 Oct 24 – 31 Mar 25	A\$5,500,000
Apr 25	1 Nov 24 – 31 Apr 25	A\$4,500,000
May 25	1 Dec 24 – 30 May 25	A\$4,500,000
Jun 25	1 Jan 25 – 30 Jun 25	A\$4,500,000

## 2. Balance sheet Covenants

MedAdvisor must ensure that Unrestricted Cash plus Account Receivables is at least **A\$6,000,000** on the balance sheet at all times while Secured Moneys are outstanding under the Facility Documents, of which **A\$1,500,000** must be held in Unrestricted Cash. This Balance Sheet Covenant must be tested and measured at the conclusion of each month.

	31-Dec-24	30-Jun-24	31-Dec-23	30-Jun-23
<b>Assets</b>				
<b>Current assets</b>				
Cash and cash equivalents	12,397,504	15,578,260	22,534,714	14,198,644
Trade and other receivables	14,547,094	14,855,424	28,431,454	11,730,635
Other current assets	2,629,357	2,076,185	2,292,337	2,181,087
<b>Total current assets</b>	<b>29,573,955</b>	<b>32,509,869</b>	<b>53,258,505</b>	<b>28,110,366</b>
<b>Non-current assets</b>				
Investments	1,923,504	962,348	962,348	-
Property, plant and equipment	249,471	261,875	377,034	531,132
Right-of-use assets	1,214,003	180,210	460,996	840,012
Intangibles	67,250,238	64,851,355	64,211,419	66,409,589
Other non-current assets	30,221	16,990	16,637	17,120
<b>Total non-current assets</b>	<b>70,667,437</b>	<b>66,272,778</b>	<b>66,028,434</b>	<b>67,797,853</b>
<b>Total assets</b>	<b>100,241,392</b>	<b>98,782,647</b>	<b>119,286,939</b>	<b>95,908,219</b>
<b>Liabilities</b>				
<b>Current liabilities</b>				
Trade and other payables	16,369,505	16,014,852	29,189,637	14,363,807
Borrowings	-	12,350,664	12,011,798	-
Other current liabilities	5,235,214	15,144,196	17,966,036	16,172,097
Lease liabilities	225,084	256,670	617,068	781,634
Employee benefits	1,478,818	1,346,143	1,257,238	1,314,542
Income tax	326,623	555,748	527,440	542,736
<b>Total current liabilities</b>	<b>23,635,244</b>	<b>45,668,273</b>	<b>61,569,217</b>	<b>33,174,816</b>
<b>Non-current liabilities</b>				
Borrowings	17,634,597	-	-	12,045,662
Lease liabilities	1,039,643	-	-	265,224
Deferred tax	1,366,284	1,355,942	1,749,422	1,771,979
Employee benefits	199,802	174,999	203,718	188,862
<b>Total non-current liabilities</b>	<b>20,240,326</b>	<b>1,530,941</b>	<b>1,953,140</b>	<b>14,271,727</b>
<b>Total liabilities</b>	<b>43,875,570</b>	<b>47,199,214</b>	<b>63,522,357</b>	<b>47,446,543</b>
<b>Net assets</b>	<b>56,365,822</b>	<b>51,583,433</b>	<b>55,764,582</b>	<b>48,461,676</b>
<b>Equity</b>				
Issued capital	116,846,498	116,545,837	115,813,950	115,411,625
Reserves	10,207,311	7,128,498	5,961,785	5,933,086
Accumulated losses	-70,687,987	-72,090,902	-66,011,153	-72,883,035
<b>Total equity</b>	<b>56,365,822</b>	<b>51,583,433</b>	<b>55,764,582</b>	<b>48,461,676</b>